FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer ; volume:21 ; number:1 ; day:12 ; month:4 ; year:2023 ; pages:1-17 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (12.4.2023), 1-17, 12.2023
- Creator
-
Liu, Yifan
Sun, Yansha
Wang, Peng
Li, Songling
Dong, Yiwei
Zhou, Min
Shi, Bizhi
Jiang, Hua
Sun, Ruixin
Li, Zonghai
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04080-z
- URN
-
urn:nbn:de:101:1-2023082609125783713264
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liu, Yifan
- Sun, Yansha
- Wang, Peng
- Li, Songling
- Dong, Yiwei
- Zhou, Min
- Shi, Bizhi
- Jiang, Hua
- Sun, Ruixin
- Li, Zonghai
- SpringerLink (Online service)
Other Objects (12)
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Engineering CAR-T cells
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Gut microbiome and CAR-T therapy
Strategies to enhance CAR-T persistence
Target selection for CAR-T therapy
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
New development in CAR-T cell therapy
Recent advances in CAR-T cell engineering
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Engineering CAR-T cells
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Gut microbiome and CAR-T therapy
Strategies to enhance CAR-T persistence
Target selection for CAR-T therapy
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
New development in CAR-T cell therapy
Recent advances in CAR-T cell engineering
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Engineering CAR-T cells
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Gut microbiome and CAR-T therapy
Strategies to enhance CAR-T persistence
Target selection for CAR-T therapy
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
New development in CAR-T cell therapy